Personalized Ovarian Cancer Treatment Options Are One Call Away
Call Now
Early, Late-Stage, and Metastatic Ovarian Cancer Treatment Options
Advanced New Ovarian Cancer Treatments Designed to Potentially
Achieve Long-Term Remission
If the core causes of your ovarian cancer remain untreated, then a complete remission from the disease may not last
for
long. We aim to overcome the potential limitations of standard ovarian cancer treatment at Envita Medical Centers, a
world-class integrative center for precision oncology, by utilizing advanced new treatments which go beyond the scope
of
conventional chemotherapy, radiation therapy, immunotherapy, hysterectomy, and other options.
Our integrative physicians have been treating all types and stages of ovarian cancers for over 25 years, with
advanced
personalized immunotherapies and a combination of several proprietary new treatments, such as CIPI™ (Chemo Immuno
Precision Injections) and GTFC™ (Genetically Targeted Fractionated Chemotherapy). These treatments are custom designed
to
strike at the root causes of cancer, even advanced ovarian cancers, and may help in sustaining long-term remissions
when
combined into a precision protocol built for our patients’ specific needs.
Our clinical experience of over 25 years in treating both chronic infections and late-stage cancers, enable us to go
beyond standard treatments like radiation therapy, brachytherapy, chemoradiation, cone biopsy or conization, and
surgeries including radical hysterectomy, radical trachelectomy, and pelvic exenteration.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
This article covers basic facts about ovarian cancer including:
How Envita Aims to Overcome the Challenges of Standard Ovarian Cancer Treatment
In our clinical opinion, the one-size-fits all treatment regimens based on ovarian cancer type and stage may not be
enough to combat the disease. Most patients, like JoAnn experience a high-risk of recurrence despite going through
maintenance therapy after the initial response to their first-line treatment based on the NCCN (National Comprehensive
Cancer Network) guidelines. Maintenance therapy, as defined by the National Cancer Institute, is given to help keep
cancer from coming back after it has disappeared following the initial therapy.
According to the American Cancer Society’s report
based on patient outcomes across standard cancer centers, which typically follow
the NCCN guidelines, the 5-year relative survival rate of ovarian cancer is 49%, highlighting the lack of response
to
conventional care in most ovarian cancer patients.
Cancer is a disease of genetic mutations, genomics, messaging, and immunity, not simply tissue or tumor types and
staging patterns, which explains why a tumor type and stage-based treatment is not always enough to overcome the
disease.
If the unique set of causes responsible for each patient’s cancer is not targeted in their treatment early
on, then the
ovarian cancer cells mutate faster, rendering treatment ineffective. To counter these challenges and combat
the disease,
we breakaway from the cookie-cutter treatment approach and provide the benefits of personalized precision
oncology,
which is a game changer in ovarian cancer treatment.
Disclaimer: Individual results will vary. Envita makes no guarantees for outcomes. Each patient case is unique. Please
consult your doctor before making any changes to your medical treatment. Not every patient is a candidate for care or
achieves these results. Treatments used in this case may not all be FDA approved for the treatment of this condition.
Personalized precision oncology treatments are crucial for attacking the core causes of the ovarian cancer, but
precision is largely missing in standard oncology treatment planning, as the NCCN guidelines do not allow healthcare
providers to deviate much from the tumor type and stage-based treatment protocols.
Envita Medical Centers Medical Team
Physicians with MD, NMD, DO, DO(h), MD(h), medical licenses
22
Pharmacists specializing in integrative agents
7
Nurses trained in precision treatment delivery
40+
You may be wondering how is it possible for Envita to go beyond the NCCN
guidelines?
The NCCN guidelines derive “effective” cancer treatment options based off large generic clinical trials determined by
cancer type and staging, without taking into account the patient’s genetic mutations. Envita, being a truly
integrative
clinic, is not bound by the NCCN restrictions, which enables us to treat you, the patient, as an individual whose
unique
mutations have caused the genetic disease. Our personalized treatment options are designed to precision-target each of
those distinct mutations, giving patients even in advanced stages, such as stage III and stage IV, a better chance at
long-term remissions. Envita’s patient-specific treatments include a powerful combination of the latest in
conventional
and natural medicines, which effectively work towards building the patient’s immune system while attacking the
cancerous
cells in the body.
In the precision medicine era, detecting and genetically characterizing residual disease after standard treatment
will
be invaluable for improving patient outcomes [1]. According to this medical study, “without methods to accurately and
rapidly detect residual disease, an early critical window to modify treatment is
therefore lost,” which is why at Envita we focus on monitoring and treating the disease in real-time.
Your unique ovarian cancer is constantly mutating and changing to fight against treatment options thrown at it,
reiterating the need for precision oncology options to aim at where your cancer is going rather than where it has
been.
Proactively treating the disease is key to reducing the risk of chemoresistance, one of the crucial challenges in
ovarian cancer treatment.
What is Chemoresistance?
Chemoresistance refers to the ability of cancer cells to evade the effect of anti-cancer medicines by pumping
them
out
of the cells. Recent studies suggest that
intra-tumor heterogeneity (ITH) is the main cause of treatment failure by chemoresistance in many types of
cancers including ovarian cancer [2]. ITH increases the ability of tumors to adapt to an incompatible
microenvironment,
which is why the development of novel strategies to overcome chemoresistance is the central goal in ovarian
cancer
research.
Personalized Precision Oncology Takes Cancer Care to the Next Level
The interaction of cancer cells with microenvironment modulates tumor heterogeneity, affecting the response to
therapy.
Precision care helps in better understanding the complex cancer microenvironment, but patients do not get access to
precision till they fail NCCN guided first-line treatments, based on tumor type and stage.
At Envita, Precision Oncology Forms the Core of Your Unique Personalized
Treatment!
The handful of patients who gain access to precision care, receive a watered-down version of Envita’s detailed
precision
algorithms, which are crucial to understand patient-specific cancer drivers, their tumor microenvironment, and all
other
factors that can impact their disease progression and treatment outcomes. To provide a comprehensive approach for
combating your disease, our detailed precision algorithms map your genetics, epigenetics, and miRNA (microRNA) in
addition to testing for heavy metals, toxins, and infections, which aid in treating the root cause of your ovarian
cancer.
Envita’s Detailed Precision Algorithms Treat Your Cancer at Multiple
Levels!
Envita Precision Algorithm vs. Standard Oncology Precision Testing
Envita Medical Centers
Standard Oncology Precision Testing
RNA Transcriptome Genes
Envita Medical Centers:20,000+
Standard Oncology:Unchecked
SNV/CNV Genes
Envita Medical Centers:452
Standard Oncology:309
Rearrangements/Fusion Genes
Envita Medical Centers:51
Standard Oncology:27
Microsatellite Instability (MSI)
Envita Medical Centers:Checked
Standard Oncology:Checked
Tumor Mutation Burden (TMB)
Envita Medical Centers:Checked
Standard Oncology:Checked
BRCA 1/2
Envita Medical Centers:Checked
Standard Oncology:Checked
Immunohistochemistry
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Chemosensitivity
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Concurrent Liquid Biopsy
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Exosomal miRNA Analysis
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Circulating Tumor Cells Enumeration
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Pharmacogenomics
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Individualized Therapy Recommendation
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Carcinogenic Exposure - Root Causes
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Inflammation Markers
Envita Medical Centers:Checked
Standard Oncology:Unchecked
Metabolic Target Drivers
Envita Medical Centers:Checked
Standard Oncology:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
Our precision algorithm helps us to personalize treatments designed for attacking the core causative factors of your
unique cancer, while reducing chances of metastatic spread to various parts of the body, such as the lymph nodes,
peritoneum, omentum, liver, lungs, or brain. A study published in the “American Journal of
Obstetrics and Gynecology,” shows how even in the early stages of the disease, due
to an aggressive spread pattern, a substantial part of patients have occult metastasis [3]. Envita’s detailed
precision
algorithms are designed to identify such early signs of metastasis and help patients progress towards a long-term
remission.
Targeted New Treatments to Potentially Improve Outcomes in All Stages of Ovarian Cancer
At Envita, targeted therapies are not just one of the treatment options for ovarian cancer, rather all our treatments
are targeted to attack each patient’s unique set of causes responsible for the growth and spread of their disease.
This
level of personalization aims to uproot the disease and rebuild your immune system’s ability to check potential
chances
of recurrence, which explains why it is crucial for both early as well as late stages of ovarian cancer.
Our unique treatments are designed on the N-of-1 model, which is like a single-subject clinical trial. The entire
treatment plan is focused on targeting each patient’s unique ovarian cancer expressions, closely monitoring their
disease, and modifying treatment, when needed, to proactively curb potential recurrence and metastases. A reactivated
immune system is crucial in sustaining long term remission, leading to a holistic recovery from ovarian cancer.
Envita’s personalized precision oncology is a four-step process with the goal of improving quality of life,
increasing
longevity, and reducing toxicity in this area of gynecologic oncology.
Step 1
Genomic Identification Decodes the Root Cause of Your Ovarian Cancer
Treating the root cause of your cancer is a key component of our multi-faceted treatment approach. Inherited genetic
irregularities, such as mutations in the BRCA 1 and BRCA 2 genes, are commonly linked to an increased risk of ovarian and breast cancer
[4], which explains why family history can be a risk-factor in certain cancers. About 44%
of women with a BRCA 1 gene mutation and 17% of those with a BRCA 2 gene mutation are expected to develop ovarian
cancer
in their lifetime.
Adapted from: Torre LA, Trabert B, DeSantis CE, et
al. Ovarian
cancer
statistics, 2018. CA Cancer J Clin.
2018;68(4):284-296. doi:10.3322/caac.21456
The BRCA genes are responsible for suppressing tumor growth, but mutated BRCA genes are incapable of functioning
properly, thus increasing the risk of cancer. The BRCA genes are critical when focusing on ovarian cancer treatment,
but
at Envita, we understand that many more genes can be identified as potential treatment targets, which led us to
develop
state-of-the-art genomic identification techniques.
Our in-depth and world-class genetic testing goes far beyond what most other cancer centers can offer in the realm of
genomics. We work with the most advanced laboratories from around the world to develop detailed testing, which lays
the
foundation to our unique precision-targeted integrative treatments.
Envita’s detailed testing not only decodes each patient’s genetic and epigenetic targets, but it also identifies
other
potential causes which could be environmental or related to infectious diseases. Envita’s peer-reviewed and published
paper on "Cancer and Infectious
Causes" elucidates this complex connection, which helps to dive into the root of each patient’s specific cause
of cancer [5].
Our proprietary testing and expertise in treating infections, helps determine the possible infectious or environmental
causes affecting your cancer and your response to treatment.
Once all the potential causes linked to your unique ovarian cancer are determined, we utilize personalized treatment
methods to attack patient-specific ovarian cancer expressions. Our enhanced detoxification technology removes toxins,
chemicals, and infectious die-off from your blood supply, paving the way for an optimized treatment response.
Immune System Targeting Helps Reduce the Risk of Chemoresistance
The immune system is an important weapon against cancer and by treating your immune system through proprietary
immunotherapies, detoxification, and nutrition, we can help your body combat your condition. The information we gather
through our extensive genomic analysis allows us to develop immunotherapy options, designed with the goal of
rebuilding
and training your immune system to target your cancer. A healthy and reactivated immune system is better equipped to
tackle chemoresistance, offering you the best chances of a holistic recovery.
Most cancer centers that do genetic testing, base their results on an old tissue biopsy, which may not be an accurate
representation of the current genetic targets as the cancer mutates fast. To affect the current genetic targets and
proactively treat the disease, we analyze the most recent mutations through Envita’s Ultra Analytes Liquid Biopsy.
Ultra Analytes Liquid Biopsy
Ultra Analytes Liquid Biopsy is deployed to identify targeted immunotherapy options to help get your
immune system working properly again.
Learn more
about
Immunotherapy
Our liquid biopsy is a blood test to gather crucial information about the genetics of your circulating ovarian cancer
cells, which helps us in custom-building a multitargeted and multifaceted treatment protocol. This information forms
the
backbone of our unique personalized precision oncology treatments and makes our approach more advanced than other
cancer
centers.
At Envita, we go beyond basic targeted immunotherapies, such as PARP inhibitors and smart drugs, that have been
helpful
in treating ovarian cancer but may not always be enough. Our advanced research in immunotherapy for
over two decades shows how genomically reprogramming your immune system cells, like natural killer (NK) cells and
dendritic cells, to identify cancer cells and mark them for immune response may help in optimizing treatment results
[6]. We offer several innovative precision-targeted immunotherapies to actively address the immune system, as well as
directly treat your unique ovarian cancer expressions.
Step 3
Personalized Drug Design Builds a Comprehensive Treatment Plan
We use a combination of FDA (Food and Drug Administration) approved drugs, repurposed drugs, and
custom-compounded
adjuvants to affect patient-specific ovarian cancer biomarkers. Biomarkers are attributes of cancer cells
containing
specific chemotherapy and immunotherapy targets. Not all biomarkers, determined via our in-depth testing, can
be
impacted by the anti-cancer medicines currently available on the market. To bridge this gap and build a truly
comprehensive treatment plan, we custom-compound adjuvants at our in-house pharmacy
FDA Approved Drugs
Optimized for your cancer mutations.
Repurposed Drugs
Off-label use of approved medications
Custom Compounded Adjuvants
Genetically typed for each patient.
Our custom-compounded adjuvants are based on advanced phytotherapeutics, including plant extracts and herbs. You may
not
be aware that many of the current oncology drugs are derived from phytotherapeutics, which makes plant-based drugs
excellent adjuvants for cancer treatment. These adjuvants may address the anomalies at cellular and molecular levels
to
help you proceed towards recovery. For instance, the patient-specific epigenetic information gathered via our detailed
testing is used to design medications which potentially promotes the expression of tumor suppressant genes, like BRCA
1
and 2, and block oncogenes that facilitate tumor growth.
As part of our personalized precision- targeted treatments, we also adjust the dosage of FDA approved and repurposed
drugs to reduce their toxicity and optimize benefits. Not every patient metabolizes at the same rate, which is why
adjusting drug dosage is crucial to ensure that the medicines have the desired effect.
Precision Deployment of New Treatments for a Holistic Recovery
Our innovative precision deployment mechanisms go beyond standard bilateral salpingo-oophorectomy (removal of both
ovaries and fallopian tubes) and cytoreductive surgeries, to reduce side effects of treatment in this area of
gynecologic oncology. Envita’s proprietary technologies are designed to cause minimum impact to the healthy cells
surrounding the cancerous cells, unlike the negative effects experienced through maximum therapeutic dose
chemotherapy.
In our clinical opinion, maximum dose untargeted chemotherapy can harm more than it helps when the wrong chemotherapy
agents are selected, and most ovarian cancer patients need chemotherapy, either before or after a tumor debulking
surgery. These mismatched chemotherapy agents can weaken the patient’s overall immune system, allowing the cancer to
become even more resistant leading to further spread.
To overcome this challenge, Envita Medical Centers’ personalized precision deployment mechanisms include advanced
immuno
agents while offering the benefits of the latest treatments, such as intraperitoneal chemotherapies, used in ovarian
and
other peritoneal cancers. Peritoneum is one of the most common sites of metastasis in cases of ovarian carcinomas.
We use intravenous deployment and interventional radiology procedures to offer a personalized and precision-targeted
treatment which provides the best possible chance of responding to care. Some of our advanced proprietary treatments
are as follows:
GTFC™ (Genetically Targeted Fractionated Chemotherapy) was developed with the goal of being more efficient at
treating
real-time genetic targets of the cancer, while reducing major side-effects by sparing the immune system and even
reactivating it. This specialized targeted treatment is unique because it increases the bioavailability of the
anti-cancer medications, as they are better absorbed by the cancerous cells.
The GTFC™ protocol is designed to best attack and kill your unique form of ovarian cancer by considering your
distinct
chemo susceptibility and the molecular profiles of your specific ovarian cancer. It takes the guesswork out of your
ovarian cancer treatment by utilizing the chemo drugs with the highest potential of impacting each patient’s unique
biomarkers. The knowledge of the appropriate chemo medicines for each individual patient allows us to use small doses
of
multiple chemo agents, increasing the mechanism of action against your specific cancer.
Envita's GTFC™ vs. Standard Chemotherapy
Envita Medical Centers
Standard Chemotherapy
Helps to improve chemotherapy delivery to the tumor using a "Trojan Horse" delivery mechanism.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses genetic molecular profiling to understand all the facets of each patient's specific cancer.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses targeted treatment to enhance the mechanism of cancer kill.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses microdosed (fractionated) chemotherapies, reducing the chances of impacting healthy cells.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Minimizes toxicity to normal cells, lowering the chance of side-effects related to administration.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Uses patient-specific supportive immunotherapy to strengthen the immune system.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Aims to reduce multidrug resistance by administering 10 - 20% of the medication delivered in maximum dose
chemo.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
Allows custom-compounded medications to be readministered in tandem to suit each patient's individual cancer
mutations.
Envita's GTFC™:Checked
Standard Chemotherapy:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
CIPI™ (Chemo Immuno Precision Injections) is a game-changer for ovarian cancer patients who may have been
unresponsive
to conventional standard of care chemotherapy procedures. It is Envita’s proprietary ovarian cancer treatment option,
which takes advantage of the targeted low-dose chemotherapy paradigm. This unique form of chemoembolization directly
targets the tumor site with precision delivery of custom-tailored chemotherapy cocktails combined with personalized
immunotherapy adjuvant care. Patient-specific micro-dosed chemotherapy and genetically targeted adjunctive
immunotherapy
attack the tumor site, while potentially minimizing the detrimental side effects to the surrounding healthy cells and
tissues.
Envita's CIPI™ vs. Standard Surgery
Envita Medical Centers
Standard Surgery
Minimally invasive so it can be performed within 40-50 minutes, without the need for large surgical
incisions.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Can be performed multiple times, even at close intervals, because there is minimal risk of post-op
complications.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
No need for general anesthesia, reducing the health risks that can result from being put into a
medically induced coma to perform an invasive surgery.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Faster recovery time as compared to traditional surgery, due to the minimally invasive administration.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Provides direct tumor targeting, which delivers patient-specific genomic agents into the tumor.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Causes a systemic immune response where the immune system is reactivated to find and attack other
metastatic cancer sites in the body.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
Performed by highly trained medical professionals in an outpatient setting, so there is no need of
hospital stays for recovery.
Envita's CIPI™:Checked
Standard Surgery:Unchecked
*Individual results may vary. Envita
makes no guarantees for outcomes.
Ovarian Cancer is divided and subdivided as follows:
Epithelial ovarian cancer: Is the most common form of ovarian carcinoma, generally affecting women
older than 65. This form of ovarian cancer
starts in the surface layer covering the ovary. Depending on the cancer cell type, epithelial ovarian cancer
is further sub-divided into High-Grade Serous Carcinomas (HGSC), Low-Grade Serous Carcinomas (LGSC),
Endometrioid, and
Mucinous.
Ovarian stromal tumors: Originates in the structural tissue cells that hold the ovary together and
are responsible for producing the female
hormones estrogen and progesterone.
Germ cell tumors of the ovary: Begins in the reproductive cells of the ovaries and is a rare type
of ovarian cancer.
Fallopian tube cancer: Originates in the fallopian tubes connecting the uterus to the ovaries and
is an exceedingly rare form of gynecologic
cancer.
Symptoms of Ovarian Cancer
Some of the symptoms to watch out for:
Abdominal pain
Bloating
Extreme fatigue
Back pain
Upset stomach
Unexplained weight loss
Changes in menstrual cycle, such as heavier or irregular bleeding
With all the research and development Envita does to customize and tailor our treatment options, it becomes clear
that
Envita is in a league of its own. Based on our own patients' statements over the years and our clinical opinion,
Envita
operates at a higher personalized integrative level, and we offer one-of-a-kind personalized integrative treatment
options with unmatched care and compassion. Our expert team undergoes extensive training of over 1,500 hours to adapt
to
our unique approach of personalized precision oncology designed to potentiate treatment benefits. If you or your loved
ones have questions about ovarian cancer, please contact our Patient Care Coordinator team at: 866-830-4576. May God
bless you on your journey to healing.
References
[1] Schwartz M, Camacho-Vanegas O, Wood AM, et al. Applying Precision Medicine to Ovarian Cancer:
Proof-of-Principle for a
"Molecular Second Look". Int J Gynecol Cancer. 2018;28(3):479-485. doi:10.1097/IGC.0000000000001190
[2] Kim S, Han Y, Kim SI, Kim HS, Kim SJ, Song YS. Tumor evolution and chemoresistance in ovarian cancer. NPJ
Precis Oncol.
2018;2:20. Published 2018 Sep 17. doi:10.1038/s41698-018-0063-0
[3] Ayhan A, Gultekin M, Celik NY, et al. Occult metastasis in early ovarian cancers: risk factors and associated
prognosis.
Am J Obstet Gynecol. 2007;196(1):81.e1-81.e816. doi:10.1016/j.ajog.2006.08.043
[4] Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for
BRCA1 and
BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416. doi:10.1001/jama.2017.7112
[5] Smith, A. , Oertle, J. and Prato, D. (2014) Cancer and Infectious Causes. Open Journal of Medical
Microbiology, 4,
161-177. doi: 10.4236/ojmm.2014.43019.
[6] Smith, A. , Oertle, J. and Prato, D. (2014) Immunotherapy in Cancer Treatment. Open Journal of Medical
Microbiology, 4,
178-191. doi: 10.4236/ojmm.2014.43020.
Our team is ready to help you get your life back! Please enter your contact information and a Patient Care
Expert will contact you shortly. If you would rather speak now, please give us a call at 1-866-830-4576.
